Pharmaceuticals

Latest California Healthline Stories

KFF Health News' 'What the Health?': The Confusing Fate of the Abortion Pill

The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.

Watch: Rulings on Abortion Pill Have Far-Reaching Repercussions

Sarah Varney, a senior correspondent for KHN, joins Ali Rogin of PBS NewsHour to discuss the ruling by a federal judge in Texas that threatens nationwide access to the widely used abortion drug mifepristone, and a separate ruling in Washington state that reached the opposite conclusion.

Gov. Newsom Wanted California to Cut Ties With Walgreens. Then Federal Law Got in the Way.

Gov. Gavin Newsom declared that California would cut ties with Walgreens after the company said it would not distribute abortion pills in some states. But federal rules make it difficult for the state to unwind its Medicaid prescription drug agreement, which paid Walgreens $1.5 billion last year.

States Try to Obscure Execution Details as Drugmakers Hinder Lethal Injection

Pharmaceutical companies have put the brakes on many states’ ability to execute prisoners using lethal injections. Lacking alternatives, states are trying to keep the public from learning details about how they carry out executions.

Sen. Sanders Shows Fire, but Seeks Modest Goals, in His Debut Drug Hearing as Health Chair

The Vermont independent and former presidential candidate was all fire and brimstone at his first hearing on drug prices as head of the Senate HELP Committee. He also pursued a more modest goal of covid vaccine price reductions. It isn’t clear whether Sanders will succeed in even that, but he has put affordability front and center.

KFF Health News' 'What the Health?': The Policy, and Politics, of Medicare Advantage

Medicare Advantage, the private-sector alternative to original Medicare, now enrolls nearly half of all Medicare beneficiaries. But it remains controversial because — while most of its subscribers like the extra benefits many plans provide — the program frequently costs the federal government more than if those seniors remained in the fully public program. That controversy […]